Skip to main content

Advertisement

Table 3 Top 10 adverse effects (3–4 grade) associated with pazopanib versus sunitinib

From: Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis

Adverse effects The number of study Pazopanib group (event/total) Sunitinib group (event/total) RR (95% CI) P value Heterogeneity
I2 (%) P value
Diarrhea 3 51/660 43/691 1.19 [0.81–1.74] 0.38 0 0.42
Fatigue 3 60/660 102/691 0.59 [0.44–0.80] 0.0006 0 0.49
Hypertension 2 83/626 93/648 0.43 [0.05–3.53] 0.43 78 0.03
Nausea/Vomiting 3 25/660 29/691 0.87 [0.52–1.46] 0.61 0 0.61
Leukopenia 2 6/626 39/648 0.26 [0.03–2.55] 0.25 84 0.01
Thrombocytopenia 2 20/626 131/648 0.16 [0.10–0.25] < 0.00001 0 0.37
Neutropenia 2 28/626 127/648 0.23 [0.15–0.34] <  0.00001 0 0.97
Increased creatinine 2 4/626 8/648 0.49 [0.15–1.63] 0.25 NA NA
Increased AST 2 71/626 16/648 4.46 [2.62–7.58] < 0.00001 0 0.69
Increased ALT 2 99/626 23/648 4.34 [2.79–6.75] < 0.00001 0 0.40
  1. Abbreviations: ALT: alanine aminotransferase, AST: aspartate aminotransferase, NA: not available